Premium
Analysis of proliferative activity using antiproliferating cell nuclear antigen antibody in colorectal cancer
Author(s) -
Nakae Shiro,
Nakamura Takeshi,
Shirono Junko,
Yoshioka Hiroshi,
Ikegawa Ryuichiro,
Miyamura Kazuo,
Kawasaki Kentaro,
Saitoh Yoichi,
Tabuchi Yoshiki
Publication year - 1995
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930600303
Subject(s) - proliferating cell nuclear antigen , immunohistochemistry , colorectal cancer , medicine , metastasis , pathology , lymphovascular invasion , antibody , stage (stratigraphy) , cancer , cancer research , biology , immunology , paleontology
Using anti‐PCNA antibody (PC10), an immunohistochemical study of the expression of PCNA in formalin‐fixed and paraffin‐embedded materials of colorectal cancer patients was performed and correlation of PCNA expression with clinicopathological findings and DNA ploidy pattern was studied. PCNA labeling rate (PCNA LR) was estimated in the advancing margin of the tumor and ranged from 23.8% to 77.9%. There was a significant difference in lymphatic vessel invasion, liver metastasis and Dukes' stage between the groups with high (>48.7) and low (<48.7) PCNA LR ( P < 0.05). No differences were seen in tumor size, histological type, lymphnode metastasis or DNA ploidy pattern. In patients with younger age, infiltration to neighboring organs, a high degree of venous invasion, and peritoneal dissemination, the frequency of high PCNA LR tended to be higher ( P <0.1). The results above suggest that a high proliferative activity as defined by evaluation of the PCNA LR at the advancing margin of the tumor may be one of the parameters of malignant potential and helpful as a predictor of liver metastasis in colorectal cancer. © 1995 Wiley‐Liss, Inc.